内蒙古十一选五兑奖期限|买内蒙古十一选五

PROJECT INTRODUCTION

Sinobioway Group Co., Ltd. (Sinobioway Group), founded in 1992, is one of the three main industrial groups affiliated with Peking University. Sinobioway Group is mainly engaged in bioeconomic system establishment and bio-industry development. It primarily invests in bio-medicine, bio-agriculture, bio-energy, bio-environment, bio-services, bio-manufacturing and bio-intelligence. The company has become a flagship enterprise in China bio-industry and has the potential to become one of the most competitive corporate groups in the world.

Sinobioway Group adheres to the concept of “Revitalizing China through Science and Education, Serving China through Industrial Development, and Reinforcing China through National Health Improvement”. Upholding the principle of “Constructing Bio-economic System and Building the Flagship of Bio-economy”, it has formed three advantages of a solid industrial foundation, an innovative economic system and a unique development philosophy. Over the past two decades since its foundation, the company has accomplished substantial pioneering and record-breaking work for China bio-industry and has made remarkable achievements, many of which have been ranked as TOP-1 in China as well as the whole world.
1) Successfully marketed the first genetic engineering drug-recombinant human interferon α1b (Sinogen), which owns independent intellectual property rights
2) Successfully marketed the world's first “inactivated SARS vaccine”
3) China's first “human avian influenza vaccine”
4) Successfully marketed the world's first H1N1 influenza A vaccine
5) Successfully marketed the world's first hand-foot-mouth disease (HFMD) vaccine
6) Successfully developed and marketed the world's first therapeutic drugs for nerve trauma - "nerve growth factor"

Tianjin Sinobioway, a subsidiary company of Sinobioway Group, has always attached importance to technological innovation and research of new products with independent intellectual property rights. In addition to independent research, communication and cooperative development with research institutes and pharmaceutical companies is also conducted, Shenzhen Xinpeng welcomes your letter or call to exchange medical technology industry trends and issue cooperation of new product development.


Cooperation concept:
Charity begins at home; Sincerity promotes success; Respect everyone as gentleman; harmony leads to large business. 


Cooperation model:
Technical cooperation: 
1) Technology optimization for single project; 
2) R & D outsourcing, intervention in pre-clinical.
3) Transfer of various types of Authorization. 
4) Long-term cooperation with the team who has a new innovative drug.
Business cooperation: introduce cooperation from domestic and foreign, act as a General Agent in China region.
Mergers and acquisitions: Target enterprise without restriction on geography or field (including chemical medicine, Chinese traditional medicine, bio-pharmaceutical or medical device), which meets our strategic requirement, can be considered.

Focus areas:
Focus on medicine area including chemical medicine, biological products, natural medicine, whose R&D stage can be pre-clinical, clinical approval, drug certificate, launch approval; Projects in the areas of liver disease, pediatrics and nephrology will be given priority.
Liver disease area: Currently it’s the most concerned area in our company, with the most comprehensive product structure. We are looking for joint projects with differentiated products including therapeutic and prophylactic drugs for antiviral, hepatoprotective effects (reducing enzyme, jaundice), fatty liver, alcoholic liver, liver fibrosis, liver cancer, corollary medical devices, IVD products and health products. We welcome these projects no matter they are under R&D or marketed.
Pediatric area: It’s the area growing rapidly. We have biological products in sales and chemical products under research; there is a rapid growth in sales of biological products. We are seeking differentiated products in this area.
Kidney disease area: With first-line biological products of renal dialysis already on market and long-lasting products under research, we are looking for special corollary products.
Brain and nerve repair area: Our first-line biological products are regarded as the first brand in the market. We are looking for special corollary products.
Anti-tumor area: We have adjuvant therapeutic biological products in sales and monoclonal antibody and anti-prostate cancer chemical products under research. We are looking for products treating cervical cancer, lung cancer and so on.
Three high areas: With first-line chemical and biological products for diabetes and hypertension under research, we are looking for special corollary products.
Characteristic Specialty: We are looking for gynecological, dermatological, ophthalmological products and special corollary products.
New treatment techniques: Car-T, precise treatment.


Business connection:
Contact person: Mr. Zhang
Tel: 86-755-26980518
Fax: 86-755-26994679
E-mail: [email protected]
内蒙古十一选五兑奖期限